<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089905</url>
  </required_header>
  <id_info>
    <org_study_id>TREX TRIAL</org_study_id>
    <nct_id>NCT03089905</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Long-term Outcomes After Two Different Anaesthetics</brief_title>
  <acronym>TREX</acronym>
  <official_title>Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanil Anaesthesia in Young Children- The TREX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sydney Children's Hospitals Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Starship Children's Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Childrenâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>John Hunter Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas, Southwestern Medical Center at Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Children's Hospital, Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is considerable evidence that most general anaesthetics modulate brain development in
      animal studies. The impact is greater with longer durations of exposure and in younger
      animals. There is great controversy over whether or not these animal data are relevant to
      human clinical scenarios.

      The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists
      such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous
      oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha
      2 agonists (such as dexmedetomidine).

      Some, but not all, human cohort studies show an association between exposure to anaesthesia
      in infancy or early childhood and later changes in cognitive tests, school performance or
      risk of developing neurodevelopmental disorders. The evidence is weak due to possible
      confounding.

      A recent well designed cohort study (the PANDA study) comparing young children that had
      hernia repair to their siblings found no evidence for a difference in a range of detailed
      neuropsychological tests. In that study most children were exposed to up to two hours of
      anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under
      regional or general anesthesia and has found no evidence for a difference in neurodevelopment
      when tested at two years of age. The GAS and PANDA studies confirm the animal data that short
      exposure is unlikely to cause any neurodevelopmental impact.

      The impact of longer exposures is still unknown. In humans the strongest evidence for an
      association between surgery and poor neurodevelopmental outcome is in infants having major
      surgery. However, this is also the group where confounding is most likely.

      The aim of our study is to see if a new combination of anaesthetic drugs results in a better
      long-term developmental outcome than the current standard of care for children having surgery
      lasting at least 2..5 hours.

      Children will be randomised to receive either a low dose
      sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic.

      They will receive a neurodevelopmental assessment at 3 years of age to assess global
      cognitive function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomised to receive either low-dose sevoflurane/dexmedetomidine/remifentanil OR standard dose sevoflurane anaesthesia.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Randomisation 1:1 will be stratified by site and age at exposure (less than 12 months and greater than or equal to 12 months). Randomisation will be in blocks of variable size. The treating anaesthetist will not be blinded to treatment arm. The assessing neuropsychologist and parents will be blinded to treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Full Scale IQ</measure>
    <time_frame>3 years of age</time_frame>
    <description>Global cognitive function as assessed by the full scale IQ score of the Wechsler Preschool and Primary School Intelligence Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of intra-operative hypotension</measure>
    <time_frame>150 minutes- duration of surgery (baseline)</time_frame>
    <description>Blood pressure measurements will be recorded during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of intra-operative bradycardia</measure>
    <time_frame>150 minutes- duration of surgery (baseline)</time_frame>
    <description>Heart rate will be recorded during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>60 minutes- after surgery</time_frame>
    <description>Pain scores will be recorded after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>60 minutes- after surgery</time_frame>
    <description>Time of removal of airway, eye-opening and discharge from PACU will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Language outcomes</measure>
    <time_frame>3 years of age</time_frame>
    <description>Clinical Evaluation of Language Fundamentals- Preschool, Version 2 (CELF-P2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention/Executive Function/impulse control</measure>
    <time_frame>3 years of age</time_frame>
    <description>A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Statue Subtest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory</measure>
    <time_frame>3 years of age</time_frame>
    <description>A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Narrative memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptive behaviour</measure>
    <time_frame>3 years of age</time_frame>
    <description>Adaptive Behavior Assessment System - Third Edition (ABAS-III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Behavior</measure>
    <time_frame>3 years of age</time_frame>
    <description>Child Behavior Checklist (CBCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive Function</measure>
    <time_frame>3 years of age</time_frame>
    <description>Behavior Rating of Executive Function- Preschool (BRIEF-P)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Skills</measure>
    <time_frame>3 years of age</time_frame>
    <description>Social Skills Improvement System (SSIS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Anesthesia</condition>
  <condition>Neurotoxicity</condition>
  <condition>Child Development</condition>
  <arm_group>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.
Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.
Sevoflurane: end tidal concentration of 0.6 -0.8% or less.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>End tidal concentration of 2.5-3.0% or greater.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.</description>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.</description>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.</description>
    <arm_group_label>Sevoflurane/dexmedetomidine/remifentanil</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Younger than 2 years (chronological age)

          -  Scheduled for surgery that is expected to last at least 2.5 hours (and/or total
             operating room time is scheduled to be at least 3 hours)

          -  Has a legally acceptable representative capable of understanding the informed consent
             document and providing consent on the participant's behalf.

        Exclusion Criteria:

          -  Known neurologic, chromosomal or congenital anomaly which is likely to be associated
             with poor neurobehavioural outcome

          -  Existing diagnosis of behavioural or neurodevelopmental disability

          -  Prematurity (defined as &lt; 36 weeks gestational age at birth)

          -  Birth weight less than 2 kg.

          -  Congenital cardiac disease requiring surgery

          -  Intracranial neurosurgery and intracranial craniofacial surgery (isolated cleft lip is
             not an exclusion)

          -  Previous cumulative exposure to general anaesthesia exceeding 2 hours

          -  Planned future cumulative exposure to anaesthesia exceeding 2 hours before the age of
             3 years.

          -  Any specific contra-indication to any aspect of the protocol

          -  Previous adverse reaction to any anaesthetic

          -  Circumstances likely to make long term follow-up impossible

          -  Living in a household where the primary language spoken at home is not a language in
             which we can administer the Wechsler Preschool and Primary School Intelligence Scale

          -  Planned postoperative sedation with any agent except opioids (e.g. benzodiazepines,
             dexmedetomidine, ketamine, barbiturates, propofol, clonidine, chloral hydrate, and
             other non-opioid sedatives). For example if such sedation is planned for
             post-operative ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Davidson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Children's Hospital, Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Davidson, MD</last_name>
    <phone>+61393455233</phone>
    <email>andrew.davidson@rch.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzette J Sheppard, Bsc (Hons)</last_name>
    <phone>+61393454901</phone>
    <email>suzette.sheppard@mcri.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Ellen McCann</last_name>
      <email>Mary.McCann@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charles Berde</last_name>
      <email>Charles.Berde@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Ellen McCann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Berde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas W Loepke, MD</last_name>
      <phone>513-636-4408</phone>
      <email>Andreas.Loepke@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Chris S Lee, MD</last_name>
      <phone>513-636-4408</phone>
      <email>Christopher.Lee@cchmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ansgar M Brambrink, MD</last_name>
      <phone>503-494-8311</phone>
      <email>brambrin@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis X McGowan</last_name>
      <email>McGowanF@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Francis X McGowan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Szmuk, MD</last_name>
      <phone>214-456-8559</phone>
      <email>Peter.Szmuk@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dean B Andropoulos, MD</last_name>
      <phone>832-826-5831</phone>
      <email>dra@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Rackemann</last_name>
      <email>kim74r@bigpond.com</email>
    </contact>
    <investigator>
      <last_name>Kim Rackemann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donald Hannah</last_name>
      <email>donald.hannah@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Shona Chung</last_name>
      <email>Shona.Chung@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Donald Hannah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin J Skowno</last_name>
      <email>justin.skowno@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Justin J Skowno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Lee-Archer</last_name>
      <email>pleearcher@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J Davidson, MD</last_name>
      <phone>+61393455233</phone>
      <email>andrew.davidson@rch.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Suzette J Sheppard</last_name>
      <phone>+61393454901</phone>
      <email>suzette.sheppard@mcri.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew J Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Britta von ungern Sternberg</last_name>
      <email>britta.regli-vonungern@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Britta von ungern Sternberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Absalom</last_name>
      <email>a.r.absalom@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Anthony Absalom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jurgen deGraaff</last_name>
      <email>j.degraaff@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Jurgen deGraaff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Frykholm</last_name>
      <email>peter.frykholm@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Peter Frykolm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laszlo Vutskits</last_name>
      <email>Laszlo.Vutskits@unige.ch</email>
    </contact>
    <investigator>
      <last_name>Laszlo Vutskits</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Disma</last_name>
      <email>nicoladisma@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nicola Disma</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suellen Walker</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>August 20, 2017</last_update_submitted>
  <last_update_submitted_qc>August 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not imagine there will be a situation where individual participant data will need to be made available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

